{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:59:30Z","timestamp":1778695170703,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Aktinische Keratosen (AK) zeichnen sich durch einen chronischen Verlauf aus, und h\u00e4ufig ist ein ganzes Hautareal betroffen (Feldkanzerisierung). Die patientenindividuelle Abw\u00e4gung therapiespezifischer Vor- und Nachteile einer feldgerichteten Therapie ist herausfordernd.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Fragestellung<\/jats:title>\n                <jats:p>Ziel der vorliegenden Arbeit war die Entwicklung und Evaluierung patientenorientierter Entscheidungskriterien, die sich f\u00fcr die pragmatische Einordnung einer AK-Feldtherapie im Behandlungsalltag bei Patienten mit besonderer Pr\u00e4disposition zur Feldkanzerisierung eignen (Patiententyp\u00a01 bis 3).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Die Entwicklung der Entscheidungskriterien und der Patiententypologie erfolgte im Rahmen eines nominalen bzw. strukturierten Multi-level-Gruppenprozesses. Anhand der patientenrelevanten Entscheidungskriterien, der verf\u00fcgbaren Evidenz aus klinischen Studien und entlang der Patiententypologie wurde ein Bewertungsalgorithmus etabliert, und feldgerichtete AK-Therapieoptionen wurden systematisch evaluiert.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Als patientenrelevante Kriterien f\u00fcr die Therapieentscheidung wurden u.\u202fa. Effektivit\u00e4t, Sicherheit, Praktikabilit\u00e4t der Therapie, Adh\u00e4renz, Kosmetik, Patientenpr\u00e4ferenz und Komorbidit\u00e4ten identifiziert und n\u00e4her spezifiziert. In Bezug auf diese Entscheidungskriterien und Patiententypen, bei denen eine Feldtherapie vorrangig indiziert ist, erf\u00fcllte die photodynamische Therapie mit Tageslicht das therapiebezogene Anforderungsprofil in besonderem Ma\u00dfe.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Die Definition von patientenrelevanten und therapiebezogenen Entscheidungskriterien in der AK-Feldtherapie erlaubt eine strukturierte und gleichzeitig praxisorientierte Herangehensweise, um spezifische Therapieoptionen einzuordnen und individuelle Therapieentscheidungen herzuleiten.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00105-020-04731-y","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T13:03:25Z","timestamp":1606914205000},"page":"314-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Entscheidungskriterien und Patientencharakteristika zur patientenorientierten Therapie der Feldkanzerisierung","Decision criteria and patient characteristics for patient-oriented treatment of field cancerization"],"prefix":"10.1007","volume":"72","author":[{"given":"W. G.","family":"Philipp-Dormston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Aschoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"von Braunm\u00fchl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Eigentler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Haalck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.-M.","family":"Thoms","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"key":"4731_CR1","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jaad.2012.09.052","volume":"68","author":"T Rosen","year":"2013","unstructured":"Rosen\u00a0T, Lebwohl\u00a0MG (2013) Prevalence and awareness of actinic keratosis: barriers and opportunities. J\u00a0Am Acad Dermatol 68:S2\u2013S9","journal-title":"J Am Acad Dermatol"},{"key":"4731_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/jdv.12102","volume":"28","author":"I Schaefer","year":"2014","unstructured":"Schaefer\u00a0I, Augustin\u00a0M, Spehr\u00a0C et\u00a0al (2014) Prevalence and risk factors of actinic keratoses in Germany\u2014analysis of multisource data. J\u00a0Eur Acad Dermatol Venereol 28:309\u2013313","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4731_CR3","volume-title":"Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis\u2014International League of Dermatological Societies in cooperation with the European Dermatology Forum","author":"RN Werner","year":"2015","unstructured":"Werner\u00a0RN, Stockfleth\u00a0E, Connolly\u00a0SM et al (2015) Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis\u2014International League of Dermatological Societies in cooperation with the European Dermatology Forum"},{"key":"4731_CR4","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1046\/j.1523-1747.2003.12246.x","volume":"120","author":"C Kennedy","year":"2003","unstructured":"Kennedy\u00a0C, Bajdik\u00a0CD, Willemze\u00a0R et\u00a0al (2003) The influence of painful sunburns and lifetime sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer. J\u00a0Invest Dermatol 120:1087\u20131093","journal-title":"J Invest Dermatol"},{"issue":"Suppl 2","key":"4731_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/jdv.14092","volume":"31","author":"E Stockfleth","year":"2017","unstructured":"Stockfleth\u00a0E (2017) The importance of treating the field in actinic keratosis. J\u00a0Eur Acad Dermatol Venereol 31(Suppl 2):8\u201311","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4731_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s13555-015-0070-9","volume":"5","author":"P Chetty","year":"2015","unstructured":"Chetty\u00a0P, Choi\u00a0F, Mitchell\u00a0T (2015) Primary care review of actinic keratosis and its therapeutic options: a global perspective. Dermatol Ther 5:19\u201335","journal-title":"Dermatol Ther"},{"key":"4731_CR7","first-page":"251","volume":"160","author":"E Stockfleth","year":"2002","unstructured":"Stockfleth\u00a0E, Ulrich\u00a0C, Meyer\u00a0T, Christophers\u00a0E (2002) Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results. Cancer Res 160:251\u2013258","journal-title":"Cancer Res"},{"issue":"5 Pt 1","key":"4731_CR8","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/0190-9622(91)70113-G","volume":"24","author":"EA Olsen","year":"1991","unstructured":"Olsen\u00a0EA, Abernethy\u00a0ML, Kulp-Shorten\u00a0C et al (1991) J\u00a0Am Acad Dermatol 24(5 Pt 1):738\u2013743","journal-title":"J Am Acad Dermatol"},{"issue":"suppl. 3","key":"4731_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.07860.x","volume":"156","author":"J R\u00f6wert-Huber","year":"2007","unstructured":"R\u00f6wert-Huber\u00a0J, Patel\u00a0MJ, Forschner\u00a0TT et al (2007) Br J Dermatol 156(suppl. 3):8\u201312","journal-title":"Br J Dermatol"},{"key":"4731_CR10","first-page":"1727","volume":"63","author":"BJM Braakhuis","year":"2003","unstructured":"Braakhuis\u00a0BJM, Tabor\u00a0MP, Kummer\u00a0JA et\u00a0al (2003) A genetic explanation of slaughter\u2019 s concept of field cancerization: evidence and clinical implications. Cancer Res 63:1727\u20131730","journal-title":"Cancer Res"},{"key":"4731_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjd.15107","volume":"176","author":"D de Berker","year":"2017","unstructured":"de Berker\u00a0D, McGregor\u00a0JM, Mohd Mustapa\u00a0MF et\u00a0al (2017) British Association of Dermatologists\u2019 guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol 176:20\u201343","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"4731_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jdv.14151","volume":"31","author":"MT Fernandez Figueras","year":"2017","unstructured":"Fernandez Figueras\u00a0MT (2017) From actinic keratosis to squamous cell carcinoma: pathophysiology revisited. J\u00a0Eur Acad Dermatol Venereol 31(Suppl 2):5\u20137","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4731_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1177\/1203475417708166","volume":"21","author":"P Fleming","year":"2017","unstructured":"Fleming\u00a0P, Zhou\u00a0S, Bobotsis\u00a0R, Lynde\u00a0C (2017) Comparison of the treatment guidelines for actinic keratosis: a critical appraisal and review. J\u00a0Cutan Med Surg 21:408\u2013417","journal-title":"J Cutan Med Surg"},{"key":"4731_CR14","unstructured":"S3-Leitlinie Aktinische Keratose und Plattenepithelkarzinom der Haut, Langversion 1.1 \u2013 M\u00e4rz 2020, AWMF-Registernummer: 032\/022OL"},{"key":"4731_CR15","unstructured":"Onkoderm e.\u202fV. Das bundesweite Netzwerk spezialisierter und innovativer Dermatologen. www.onkoderm.de. Zugegriffen: 01.12.2020"},{"issue":"6","key":"4731_CR16","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1111\/j.1365-2133.2012.10833.x","volume":"166","author":"SR Wiegell","year":"2012","unstructured":"Wiegell\u00a0SR, Fabricius\u00a0S, Gniadecka\u00a0M et al (2012) Daylight-mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp: a randomized multicentre study. Br J Dermatol 166(6):1327\u20131332","journal-title":"Br J Dermatol"},{"issue":"2","key":"4731_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/jdv.15185","volume":"33","author":"T Dirschka","year":"2019","unstructured":"Dirschka\u00a0T, Ekanayake-Bohlig\u00a0S, Dominicus\u00a0R et al (2019) A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the treatment of actinic keratosis. J\u00a0Eur Acad Dermatol Venereol 33(2):288\u2013297","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"4731_CR18","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/jdv.14703","volume":"32","author":"WG Philipp-Dormston","year":"2018","unstructured":"Philipp-Dormston\u00a0WG, M\u00fcller\u00a0K, Novak\u00a0B et al (2018) Patient-reported health outcomes in patients with non-melanoma skin cancer and actinic keratosis: results from a\u00a0large-scale observational study analysing effects of diagnoses and disease progression. J\u00a0Eur Acad Dermatol Venereol 32(7):1138\u20131146","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4731_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12895-017-0064-7","volume":"17","author":"E Kohl","year":"2017","unstructured":"Kohl\u00a0E, Koller\u00a0M, al Zeman\u00a0F (2017) Daylight photodynamic therapy versus cryosurgery for the treatment and prophylaxis of actinic keratoses of the face\u2014protocol of a\u00a0multicenter, prospective, randomized, controlled, two-armed study. BMC Dermatol 17:12","journal-title":"BMC Dermatol"},{"key":"4731_CR20","first-page":"1240","volume":"13","author":"WG Philipp-Dormston","year":"2015","unstructured":"Philipp-Dormston\u00a0WG, Karrer\u00a0S, Petering\u00a0H et al (2015) Daylight PDT with MAL\u2014current data and practical recommendations of an expert panel. J\u00a0Dtsch Dermatol Ges 13:1240\u20131249","journal-title":"J Dtsch Dermatol Ges"},{"issue":"7","key":"4731_CR21","first-page":"632","volume":"11","author":"RM Szeimies","year":"2013","unstructured":"Szeimies\u00a0RM, Lischner\u00a0S, Philipp-Dormston\u00a0W et al (2013) Photodynamic therapy for skin rejuvenation: treatment options\u2014results of a\u00a0consensus conference of an expert group for aesthetic photodynamic therapy. J\u00a0Dtsch Dermatol Ges 11(7):632\u2013636","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"4731_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/ijms17030309","volume":"17","author":"C Lerche","year":"2016","unstructured":"Lerche\u00a0C, Heerfordt\u00a0IM, Heydenreich\u00a0J et\u00a0al (2016) Alternatives to outdoor daylight illumination for photodynamic therapy\u2014use of greenhouses and artificial light sources. Int J Mol Sci 17(3):309","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4731_CR23","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/bjd.13420","volume":"172","author":"C Kellner","year":"2015","unstructured":"Kellner\u00a0C, Bauriedl\u00a0S, Hollstein\u00a0S et al (2015) Simulated-daylight photodynamic therapy with BF-200 aminolaevulinic acid for actinic keratosis: assessment of the efficacy and tolerability in a\u00a0retrospective study. Br\u00a0J Dermatol 172(4):1146\u20131148. https:\/\/doi.org\/10.1111\/bjd.13420","journal-title":"J Dermatol"},{"key":"4731_CR24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.pdpdt.2019.05.015","volume":"27","author":"C von Dobbeler","year":"2019","unstructured":"von Dobbeler\u00a0C, Schmitz\u00a0L, Dicke\u00a0K et\u00a0al (2019) PDT with PPIX absorption peaks adjusted wavelengths: safety and efficacy of a\u00a0new irradiation procedure for actinic keratoses on the head. Photodiagnosis Photodyn Ther 27:198\u2013202","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"4731_CR25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12181-018-0271-4","volume":"12","author":"C Albus","year":"2018","unstructured":"Albus\u00a0C et\u00a0al (2018) K Bedeutung von psychosozialen Faktoren in der Kardiologie \u2013 Update 2018. Kardiologe 12:312\u2013331","journal-title":"Kardiologe"},{"key":"4731_CR26","doi-asserted-by":"publisher","first-page":"e0161840","DOI":"10.1371\/journal.pone.0161840","volume":"11","author":"P Steca","year":"2016","unstructured":"Steca\u00a0P, Addario\u00a0M, Magrin\u00a0ME et\u00a0al (2016) A type A and type D combined personality typology in essential hypertension and acute coronary syndrome patients: associations with demographic, psychological, clinical, and lifestyle indicators. PLoS ONE 11:e161840","journal-title":"PLoS ONE"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04731-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-020-04731-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04731-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T12:07:05Z","timestamp":1617278825000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-020-04731-y"}},"subtitle":["Ein standardisierter Bewertungsalgorithmus f\u00fcr individuelle Behandlungskonzepte","Standardized algorithm for personalized treatment concepts"],"short-title":[],"issued":{"date-parts":[[2020,12,2]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["4731"],"URL":"https:\/\/doi.org\/10.1007\/s00105-020-04731-y","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,2]]},"assertion":[{"value":"2 December 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die Treffen der Expertengruppe und die Vorbereitung des Manuskriptes wurden durch LEO Pharma unterst\u00fctzt. W.G.\u00a0Philipp-Dormston gibt an, Honorare f\u00fcr wissenschaftliche Vortr\u00e4ge, klinische Studien und Beratungst\u00e4tigkeiten von AbbVie\/Allergan, Almirall-Hermal, Beiersdorf\/Eucerin, Benevi, Biofrontera, Galderma, La Roche-Posay, LEO Pharma, Merz und SkinCeuticals erhalten zu haben. R.\u00a0Aschoff gibt an, Honorare f\u00fcr wissenschaftliche Vortr\u00e4ge und Beratungst\u00e4tigkeiten von LEO Pharma, Biofrontera, Galderma und Meda erhalten zu haben. T.\u00a0von Braunm\u00fchl gibt an, Honorare von Almirall-Hermal, LEO Pharma und Meda Pharma erhalten zu haben. T.\u00a0Eigentler gibt an, Honorare f\u00fcr Beratungst\u00e4tigkeiten von Bristol-Myers Squibb, Roche, Novartis, LEO Pharma, Pierre Fabre und MSD erhalten zu haben. Dar\u00fcber hinaus erhielt er Honorare f\u00fcr wissenschaftliche Vortr\u00e4ge von Roche, MSD, Bristol-Myers Squibb und Novartis. K.-M.\u00a0Thoms gibt an, Honorare f\u00fcr wissenschaftliche Vortr\u00e4ge und Beratungst\u00e4tigkeiten von LEO Pharma, Galderma, Bristol-Myers Squibb, MSD, Roche, Novartis, Pierre Fabre und AbbVie erhalten zu haben. T.\u00a0Haalck gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}